MX2009011020A - Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. - Google Patents
Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.Info
- Publication number
- MX2009011020A MX2009011020A MX2009011020A MX2009011020A MX2009011020A MX 2009011020 A MX2009011020 A MX 2009011020A MX 2009011020 A MX2009011020 A MX 2009011020A MX 2009011020 A MX2009011020 A MX 2009011020A MX 2009011020 A MX2009011020 A MX 2009011020A
- Authority
- MX
- Mexico
- Prior art keywords
- oxide
- disorders
- dopamine receptor
- cardiovascular side
- modulators
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical class NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title abstract 3
- 102000015554 Dopamine receptor Human genes 0.000 title abstract 2
- 108050004812 Dopamine receptor Proteins 0.000 title abstract 2
- 150000001204 N-oxides Chemical class 0.000 title abstract 2
- 239000003381 stabilizer Substances 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0700893 | 2007-04-12 | ||
| PCT/SE2008/050414 WO2008127188A1 (en) | 2007-04-12 | 2008-04-11 | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009011020A true MX2009011020A (es) | 2009-10-30 |
Family
ID=39864178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011020A MX2009011020A (es) | 2007-04-12 | 2008-04-11 | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9139525B2 (enExample) |
| EP (1) | EP2146961B1 (enExample) |
| JP (1) | JP5393654B2 (enExample) |
| CN (1) | CN101711236B (enExample) |
| AU (1) | AU2008239841B2 (enExample) |
| BR (1) | BRPI0810161A2 (enExample) |
| CA (1) | CA2683719C (enExample) |
| CY (1) | CY1115337T1 (enExample) |
| DK (1) | DK2146961T3 (enExample) |
| ES (1) | ES2458592T3 (enExample) |
| HR (1) | HRP20140380T1 (enExample) |
| IL (1) | IL201401A (enExample) |
| MX (1) | MX2009011020A (enExample) |
| NZ (1) | NZ580856A (enExample) |
| PL (1) | PL2146961T3 (enExample) |
| PT (1) | PT2146961E (enExample) |
| RU (1) | RU2470013C2 (enExample) |
| SI (1) | SI2146961T1 (enExample) |
| WO (1) | WO2008127188A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| US8673962B2 (en) | 2008-11-24 | 2014-03-18 | Integrative Research Laboratories Sweden Ab | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| WO2012028635A1 (en) | 2010-09-03 | 2012-03-08 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| AU2012306386B2 (en) | 2011-09-07 | 2017-06-15 | Teva Pharmaceuticals International Gmbh | Polymorphic form of pridopidine hydrochloride |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| EP2844346B1 (en) | 2012-04-04 | 2020-01-01 | Prilenia Neurotherapeutics Ltd. | Pharmaceutical compositions for combination therapy |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| ES2879631T3 (es) | 2013-06-21 | 2021-11-22 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de la enfermedad de Huntington |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138130A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| IL268125B2 (en) | 2017-01-20 | 2023-04-01 | Prilenia Neurotherapeutics Ltd | Pridopidine for the treatment of fragile x syndrome |
| PT4154882T (pt) | 2017-08-14 | 2025-11-19 | Prilenia Neurotherapeutics Ltd | Tratamento da esclerose lateral amiotrófica com pridopidina |
| JP2020532517A (ja) | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| BR112021015346A2 (pt) | 2019-02-04 | 2021-10-05 | Prilenia Neurotherapeutics Ltd. | Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1217296A (en) | 1917-01-11 | 1917-02-27 | Lewis A Peckham | Shock-absorber. |
| US2813097A (en) | 1955-08-16 | 1957-11-12 | Upjohn Co | 3-hydroxy-n-methylmorphinan-n-oxide |
| US2813098A (en) | 1955-08-16 | 1957-11-12 | Upjohn Co | 3-methoxy-n-methylmorphinan n-oxide |
| US3131185A (en) | 1959-03-18 | 1964-04-28 | Orsymonde | Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters |
| BE638369A (enExample) | 1962-10-10 | |||
| CH481124A (de) | 1966-09-21 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen |
| AU658134B2 (en) | 1989-12-28 | 1995-04-06 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| AU653837B2 (en) | 1991-04-17 | 1994-10-13 | Pharmacia & Upjohn Company | Substituted phenylazacycloalkanes as CNS agents |
| WO1993000313A2 (en) | 1991-06-27 | 1993-01-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| IL112099A (en) * | 1993-12-23 | 1999-07-14 | Ortho Pharma Corp | N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them |
| CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
| ATE253364T1 (de) * | 1998-11-23 | 2003-11-15 | Sepracor Inc | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE0200301D0 (sv) * | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
| JP2008501749A (ja) | 2004-06-08 | 2008-01-24 | ニューロサーチ スウェーデン アクチボラゲット | ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン |
| MXPA06013944A (es) * | 2004-06-08 | 2007-10-08 | Neurosearch Sweden Ab | Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina. |
| AU2005273961A1 (en) * | 2004-08-11 | 2006-02-23 | Williamsburg Holdings Llc | Noncardiotoxic pharmaceutical compounds |
| CN101056854B (zh) * | 2004-10-13 | 2013-06-05 | Nsab神经研究瑞典公司分公司 | 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法 |
| PL1919883T3 (pl) | 2005-08-22 | 2009-06-30 | Solvay Pharm Bv | N-TLENKI JAKO PROLEKI PIPERAZYNOWYCH oraz PIPERYDYNOWYCH POCHODNYCH |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| MX2008013887A (es) * | 2006-05-02 | 2009-01-29 | Solvay Pharm Bv | N-oxidos de derivados de piridilmetilpiperazina y piridilmetilpiperdina. |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| WO2011107593A1 (en) * | 2010-03-05 | 2011-09-09 | Dsm Ip Assets B.V. | Process for the production of an uhmwpe article |
| WO2012028635A1 (en) * | 2010-09-03 | 2012-03-08 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| AU2012306386B2 (en) | 2011-09-07 | 2017-06-15 | Teva Pharmaceuticals International Gmbh | Polymorphic form of pridopidine hydrochloride |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| EP2844346B1 (en) * | 2012-04-04 | 2020-01-01 | Prilenia Neurotherapeutics Ltd. | Pharmaceutical compositions for combination therapy |
| EP2900226A4 (en) * | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
| EA201590655A8 (ru) * | 2012-09-27 | 2016-07-29 | Тева Фармасьютикал Индастриз Лтд. | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений |
-
2008
- 2008-04-11 DK DK08741904T patent/DK2146961T3/da active
- 2008-04-11 NZ NZ580856A patent/NZ580856A/en unknown
- 2008-04-11 ES ES08741904T patent/ES2458592T3/es active Active
- 2008-04-11 PT PT08741904T patent/PT2146961E/pt unknown
- 2008-04-11 AU AU2008239841A patent/AU2008239841B2/en not_active Ceased
- 2008-04-11 RU RU2009141300/04A patent/RU2470013C2/ru not_active IP Right Cessation
- 2008-04-11 MX MX2009011020A patent/MX2009011020A/es unknown
- 2008-04-11 CN CN2008800175988A patent/CN101711236B/zh not_active Expired - Fee Related
- 2008-04-11 CA CA2683719A patent/CA2683719C/en not_active Expired - Fee Related
- 2008-04-11 WO PCT/SE2008/050414 patent/WO2008127188A1/en not_active Ceased
- 2008-04-11 SI SI200831188T patent/SI2146961T1/sl unknown
- 2008-04-11 BR BRPI0810161 patent/BRPI0810161A2/pt not_active IP Right Cessation
- 2008-04-11 EP EP20080741904 patent/EP2146961B1/en not_active Not-in-force
- 2008-04-11 US US12/595,472 patent/US9139525B2/en active Active
- 2008-04-11 PL PL08741904T patent/PL2146961T3/pl unknown
- 2008-04-11 JP JP2010502976A patent/JP5393654B2/ja not_active Expired - Fee Related
- 2008-04-11 HR HRP20140380AT patent/HRP20140380T1/hr unknown
-
2009
- 2009-10-11 IL IL201401A patent/IL201401A/en not_active IP Right Cessation
-
2014
- 2014-04-25 CY CY20141100304T patent/CY1115337T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2458592T3 (es) | 2014-05-06 |
| WO2008127188A1 (en) | 2008-10-23 |
| PL2146961T3 (pl) | 2014-09-30 |
| CN101711236B (zh) | 2012-10-31 |
| BRPI0810161A2 (pt) | 2014-12-30 |
| CY1115337T1 (el) | 2017-01-04 |
| CN101711236A (zh) | 2010-05-19 |
| JP2010523651A (ja) | 2010-07-15 |
| US20100105736A1 (en) | 2010-04-29 |
| IL201401A0 (en) | 2010-05-31 |
| CA2683719A1 (en) | 2008-10-23 |
| AU2008239841A1 (en) | 2008-10-23 |
| EP2146961A4 (en) | 2011-08-03 |
| US9139525B2 (en) | 2015-09-22 |
| RU2009141300A (ru) | 2011-05-20 |
| CA2683719C (en) | 2015-07-14 |
| PT2146961E (pt) | 2014-04-30 |
| EP2146961B1 (en) | 2014-01-29 |
| SI2146961T1 (sl) | 2014-08-29 |
| DK2146961T3 (da) | 2014-04-28 |
| NZ580856A (en) | 2011-11-25 |
| HRP20140380T1 (hr) | 2014-08-15 |
| RU2470013C2 (ru) | 2012-12-20 |
| JP5393654B2 (ja) | 2014-01-22 |
| AU2008239841B2 (en) | 2013-07-18 |
| EP2146961A1 (en) | 2010-01-27 |
| IL201401A (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011020A (es) | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. | |
| JO2645B1 (en) | Vehicles | |
| CL2007003261A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, tales como esquizofrenia, | |
| GEP20135793B (en) | Heteroaryls amide derivatives and their use as glucokinase activators | |
| MX2008012400A (es) | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. | |
| JO2756B1 (en) | The second preparation of aqueous pyrimidnon containing 4- (4-ciano-2-2 thiourail) and its use) | |
| MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
| UA96447C2 (ru) | Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы | |
| MX2009008159A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| NZ612000A (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
| MY156288A (en) | Pharmaceutical formulations containing dopamine receptor ligands. | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| MX2009011358A (es) | Derivados de pirimidinona y metodos para su uso. | |
| JO2686B1 (en) | Vehicles | |
| GEAP202014908A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| MX2010002899A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3. | |
| IL189298A0 (en) | 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission | |
| MY143581A (en) | Carboxamide derivatives as muscarinic receptor antagonists | |
| MX340807B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| MX2010004003A (es) | N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas. | |
| MX2011006843A (es) | Dihidropiridona-amidas como moduladores de p2x7. | |
| PH12014502803B1 (en) | Camsylate salt | |
| MX2009008616A (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion. | |
| TN2009000014A1 (en) | Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same | |
| MX2011008850A (es) | Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |